PH12016501310A1 - Pharmaceutical compositions comprising azd9291 - Google Patents

Pharmaceutical compositions comprising azd9291

Info

Publication number
PH12016501310A1
PH12016501310A1 PH12016501310A PH12016501310A PH12016501310A1 PH 12016501310 A1 PH12016501310 A1 PH 12016501310A1 PH 12016501310 A PH12016501310 A PH 12016501310A PH 12016501310 A PH12016501310 A PH 12016501310A PH 12016501310 A1 PH12016501310 A1 PH 12016501310A1
Authority
PH
Philippines
Prior art keywords
azd9291
pharmaceutical compositions
pharmaceutical
compositions
enamide
Prior art date
Application number
PH12016501310A
Inventor
Wilson David
Finnie Cindy
Raw Steven Anthony
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50191689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12016501310(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PH12016501310A1 publication Critical patent/PH12016501310A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl- methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop- 2-enamide ("AZD9291") or a pharmaceutically acceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
PH12016501310A 2014-01-02 2016-06-30 Pharmaceutical compositions comprising azd9291 PH12016501310A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1400034.3A GB201400034D0 (en) 2014-01-02 2014-01-02 Pharmaceutical Compositions comprising AZD9291
PCT/GB2015/050001 WO2015101791A1 (en) 2014-01-02 2015-01-02 Pharmaceutical compositions comprising azd9291

Publications (1)

Publication Number Publication Date
PH12016501310A1 true PH12016501310A1 (en) 2016-09-14

Family

ID=50191689

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12016501310A PH12016501310A1 (en) 2014-01-02 2016-06-30 Pharmaceutical compositions comprising azd9291

Country Status (37)

Country Link
US (4) US10183020B2 (en)
EP (1) EP3089741B1 (en)
JP (1) JP6588915B2 (en)
KR (1) KR102336378B1 (en)
CN (2) CN114712362A (en)
AR (1) AR098989A1 (en)
AU (1) AU2015204218B2 (en)
CA (1) CA2933403C (en)
CL (1) CL2016001609A1 (en)
CR (1) CR20160310A (en)
CY (1) CY1124848T1 (en)
DK (1) DK3089741T3 (en)
DO (1) DOP2016000156A (en)
EA (1) EA034243B9 (en)
ES (1) ES2873226T3 (en)
GB (1) GB201400034D0 (en)
GT (1) GT201600142A (en)
HK (1) HK1225655A1 (en)
HR (1) HRP20210749T1 (en)
HU (1) HUE054344T2 (en)
IL (1) IL246186B (en)
LT (1) LT3089741T (en)
MX (1) MX367358B (en)
MY (1) MY183536A (en)
NI (1) NI201600098A (en)
NZ (1) NZ721298A (en)
PE (1) PE20161170A1 (en)
PH (1) PH12016501310A1 (en)
PL (1) PL3089741T3 (en)
PT (1) PT3089741T (en)
RS (1) RS61927B1 (en)
SG (1) SG11201605339QA (en)
SI (1) SI3089741T1 (en)
TW (1) TWI702953B (en)
UY (1) UY35933A (en)
WO (1) WO2015101791A1 (en)
ZA (1) ZA201605300B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
WO2017205459A1 (en) 2016-05-26 2017-11-30 Kalyra Pharmaceuticals, Inc. Egfr inhibitor compounds
CN108057036B (en) * 2016-11-07 2023-06-13 正大天晴药业集团股份有限公司 Solid pharmaceutical composition of EGFR inhibitor
CN107176954B (en) * 2017-06-02 2019-01-11 无锡双良生物科技有限公司 A kind of pharmaceutical salts and its crystal form, preparation method and application of EGFR inhibitor
CN110013468B (en) * 2018-01-09 2022-02-18 北京福元医药股份有限公司 AZD9291 deuterated derivative pharmaceutical preparation
WO2019138346A1 (en) * 2018-01-10 2019-07-18 Alembic Pharmaceuticals Limited Pharmaceutical composition of osimertinib
SG11202007414XA (en) * 2018-02-12 2020-09-29 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
US20210369732A1 (en) * 2018-03-01 2021-12-02 Astrazeneca Ab PHARMACEUTICAL COMPOSITIONS COMPRISING (2S)-N-{(1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-yl)PHENYL]ETHYL}-1,4-OXAZEPANE-2-CARBOXAMIDE
CN109496150A (en) * 2018-03-23 2019-03-19 无锡双良生物科技有限公司 A kind of pharmaceutical composition and its preparation method and application
KR20200043618A (en) 2018-10-18 2020-04-28 주식회사유한양행 Pharmaceutical composition for oral administration comprising an aminopyrimidine derivative or its salt
MA55508A (en) 2019-03-29 2022-02-09 Astrazeneca Ab OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
JP2023510426A (en) 2020-01-20 2023-03-13 アストラゼネカ・アクチエボラーグ Epidermal growth factor receptor tyrosine kinase inhibitors for treating cancer
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110376A (en) * 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof
SE9802973D0 (en) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
AU2001248751A1 (en) * 2000-04-12 2001-10-23 Banyu Pharmaceutical Co. Ltd. Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
ES2286406T3 (en) 2002-02-26 2007-12-01 Astrazeneca Ab PHARMACEUTICAL FORMULATION OF IRESSA THAT INCLUDES A WATER SOLUBLE CELLULOSE DERIVATIVE.
EP1799190A1 (en) * 2004-10-05 2007-06-27 Altana Pharma AG Oral pharmaceutical preparation for proton pump antagonists
ES2279715B1 (en) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. ORAL FORMULATION OF OLANZAPINE.
NZ570381A (en) * 2006-02-09 2011-02-25 Daiichi Sankyo Co Ltd Anti-cancer pharmaceutical composition
JP5576922B2 (en) * 2006-04-20 2014-08-20 信越化学工業株式会社 Solid formulation comprising an enteric solid dispersion
US8247423B2 (en) * 2007-07-12 2012-08-21 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
WO2012139736A1 (en) 2011-04-11 2012-10-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Pharmaceutical composition comprising bosentan
KR101317809B1 (en) 2011-06-07 2013-10-16 한미약품 주식회사 Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cell and non-metalic salt lubricant
CN105254616B (en) * 2011-07-27 2017-10-17 阿斯利康(瑞典)有限公司 The substituted amines of N (nitrobenzophenone of 2 methoxyl group 5) pyrimidine 2 and its salt
EP4218740A1 (en) * 2012-01-13 2023-08-02 XSpray Pharma AB (publ) Novel compositions
WO2013160916A1 (en) 2012-04-25 2013-10-31 Hetero Research Foundation Sunitinib malate solid dispersion
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291

Also Published As

Publication number Publication date
PL3089741T3 (en) 2021-09-27
CY1124848T1 (en) 2022-11-25
EP3089741B1 (en) 2021-03-10
NZ721298A (en) 2017-10-27
US20200360378A1 (en) 2020-11-19
JP6588915B2 (en) 2019-10-09
AR098989A1 (en) 2016-06-22
ES2873226T3 (en) 2021-11-03
CR20160310A (en) 2016-09-23
CN114712362A (en) 2022-07-08
GT201600142A (en) 2019-08-12
SI3089741T1 (en) 2021-08-31
ZA201605300B (en) 2022-10-26
US20160324854A1 (en) 2016-11-10
PT3089741T (en) 2021-06-11
CN105848647B (en) 2022-04-26
US20220395502A1 (en) 2022-12-15
US20190111057A1 (en) 2019-04-18
EA034243B1 (en) 2020-01-21
MX2016008744A (en) 2016-09-08
PE20161170A1 (en) 2016-11-24
GB201400034D0 (en) 2014-02-19
DK3089741T3 (en) 2021-06-07
WO2015101791A1 (en) 2015-07-09
TWI702953B (en) 2020-09-01
CA2933403A1 (en) 2015-07-09
CA2933403C (en) 2022-03-29
NI201600098A (en) 2016-12-20
EA034243B9 (en) 2020-04-10
MY183536A (en) 2021-02-25
UY35933A (en) 2015-07-31
TW201609101A (en) 2016-03-16
MX367358B (en) 2019-08-16
EA201691242A1 (en) 2016-12-30
LT3089741T (en) 2021-06-10
SG11201605339QA (en) 2016-07-28
RS61927B1 (en) 2021-06-30
CL2016001609A1 (en) 2016-12-09
HK1225655A1 (en) 2017-09-15
HRP20210749T1 (en) 2021-06-25
HUE054344T2 (en) 2021-08-30
IL246186B (en) 2020-07-30
DOP2016000156A (en) 2016-08-15
KR20160101720A (en) 2016-08-25
JP2017501201A (en) 2017-01-12
KR102336378B1 (en) 2021-12-08
AU2015204218A1 (en) 2016-07-07
AU2015204218B2 (en) 2017-06-15
IL246186A0 (en) 2016-07-31
EP3089741A1 (en) 2016-11-09
CN105848647A (en) 2016-08-10
US10183020B2 (en) 2019-01-22

Similar Documents

Publication Publication Date Title
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2016006053A (en) Selective pyy compounds and uses thereof.
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
EA201890534A1 (en) NEW ANNELED PHENOXYCETAMIDES
TN2016000491A1 (en) Carboxamide derivatives.
TN2016000489A1 (en) Carboxamide derivatives.
SA519410865B1 (en) Coumarin-like Cyclic Compound as MEK Inhibitor and Use Thereof
PH12017501444A1 (en) (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
PH12019500567A1 (en) Crystalline forms
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
AU2015280874A1 (en) Novel heterocyclic compound
EA202090913A1 (en) COMPOSITION OF MODIFIED RELEASE TABLETS CONTAINING MIRABEGRON
PH12017501832A1 (en) Stabilized pharmaceutical composition
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
EA201991286A1 (en) A SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING TENOFOVIR AND EMTRITSITABIN
PH12016502527B1 (en) Stabilized desmopressin
MX2017013103A (en) Methods for the treatment of cardiovascular disorders.
PH12018500946A1 (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
TR201721065A2 (en) Lyophilized pharmaceutical formulations comprising dexmedetomidine
GR1008804B (en) Medical compositions containing hyaluronic acid or salts thereof, amino acids, vitamins, non-organic salts and other components
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids